Vabysmo (faricimab-svoa)

Adult Dosing .

Dosage forms:  INJ (pre-filled syringe): 6 mg per 0.05 mL; INJ (vial): 6 mg per 0.05 mL

Special Note

[formulation clarification]

Info: nonproprietary name = faricimab-svoa

age-related macular degeneration, neovascular

[q8wk regimen]

Dose: 6 mg intravitreally q8wk at wk 20, 28, 36, 44; Start: 6 mg intravitreally qmo x4 doses; Info: some pts may require qmo maint. dosing

[q12wk regimen]

Dose: 6 mg intravitreally q12wk at wk 24, 36, 48; Start: 6 mg intravitreally qmo x4 doses; Info: some pts may require qmo maint. dosing

[q16wk regimen]

Dose: 6 mg intravitreally q16wk at wk 28 and 44; Start: 6 mg intravitreally qmo x4 doses; Info: some pts may require qmo maint. dosing

diabetic macular edema

[fixed interval regimen]

Dose: 6 mg intravitreally q8wk; Start: 6 mg intravitreally qmo x6 doses; Info: some pts may require qmo maint. dosing

[variable interval regimen]

Dose: 6 mg intravitreally q4-16wk; Start: 6 mg intravitreally qmo for at least 4 doses; Info: may extend dosing interval up to 4wk increments or decr. up to 8wk increments based on dz activity

macular edema, retinal vein occlusion-associated

[6 mg intravitreally qmo x6mo]

renal dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined

HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.